Operating Lease, Right-of-Use Asset of ImmunoGen, Inc. from 31 Mar 2019 to 30 Sep 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
ImmunoGen, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 30 Sep 2023.
  • ImmunoGen, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2023 was $8,338,000, a 23% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

ImmunoGen, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2023 $8,338,000 -$2,471,000 -23% 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $8,997,000 -$2,364,000 -21% 30 Jun 2023 10-Q 31 Jul 2023 2023 Q2
Q1 2023 $9,627,000 -$2,261,000 -19% 31 Mar 2023 10-Q 28 Apr 2023 2023 Q1
Q4 2022 $10,231,000 -$2,161,000 -17% 31 Dec 2022 10-Q 02 Nov 2023 2023 Q3
Q3 2022 $10,809,000 -$1,936,000 -15% 30 Sep 2022 10-Q 04 Nov 2022 2022 Q3
Q2 2022 $11,361,000 -$1,845,000 -14% 30 Jun 2022 10-Q 01 Aug 2022 2022 Q2
Q1 2022 $11,888,000 -$1,760,000 -13% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $12,392,000 -$1,680,000 -12% 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 $12,745,000 -$1,732,000 -12% 30 Sep 2021 10-Q 29 Oct 2021 2021 Q3
Q2 2021 $13,206,000 -$1,658,000 -11% 30 Jun 2021 10-Q 30 Jul 2021 2021 Q2
Q1 2021 $13,648,000 -$1,586,000 -10% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $14,072,000 -$1,515,000 -9.7% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 $14,477,000 -$1,447,000 -9.1% 30 Sep 2020 10-Q 06 Nov 2020 2020 Q3
Q2 2020 $14,864,000 -$1,525,000 -9.3% 30 Jun 2020 10-Q 05 Aug 2020 2020 Q2
Q1 2020 $15,234,000 -$1,471,000 -8.8% 31 Mar 2020 10-Q 05 May 2020 2020 Q1
Q4 2019 $15,587,000 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $15,924,000 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 $16,389,000 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 $16,705,000 31 Mar 2019 10-Q 07 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.